Most Read Articles
Pearl Toh, 18 Feb 2016
Treatment with eluxadoline, a new oral medication, relieved two major symptoms of irritable bowel syndrome with diarrhoea (IBS-D) — abdominal pain and diarrhoea, according to a study based on two phase III randomized controlled trials. [N Engl J Med 2016;374:242-253]
Roshini Claire Anthony, 20 Mar 2018

Individuals with type 2 diabetes (T2D) who initiate therapy with sodium glucose cotransporter-2 (SGLT-2) inhibitors have lower risks of all-cause death and cardiovascular (CV) outcomes, specifically myocardial infarction (MI) and stroke, compared with those who initiate other glucose-lowering therapies, according to results from the CVD-REAL* 2 study.

Jairia Dela Cruz, 05 Mar 2018
Abaloparatide appears to produce significant increases in the bone mass density (BMD), as well as nominal reductions in fractures, in very elderly women with osteoporosis, with a safety profile similar to that in the overall study population, according to a posthoc analysis of the phase III ACTIVE trial.
Jairia Dela Cruz, 09 Jan 2017
The sulfonylurea glimepiride may pose an increased risk of hypoglycaemia in a subgroup of elderly type 2 diabetes (T2D) patients with lower β-cell function when added to a metformin regimen, according to a post-hoc analysis of data from the GENERATION* trial.

Dose-rounding strategy of cancer agents results in potential cost, waste avoidance

13 Feb 2018

Significant cost and waste savings can be achieved by rounding monoclonal antibodies to the nearest vial size, with minimal deviation from the actual ordered dose, a recent study suggests.

Of the 436 doses included, 237 were not rounded to the nearest vial size and thus was excluded from the analysis. Using actual wholesale price, the cost of waste related to these doses was $108,013.64. On the other hand, cost savings associated with the theoretical dose calculations were estimated at $83,595.53.

Dose rounding to the nearest vial size led to a median deviation from the ordered dose of 6.7 percent (range, 1.4‒20 percent).

In one study that involved three costly cancer agents (bevacizumab, trastuzumab and cetuximab), a 10-percent dose reduction for all cases was achieved after consultation with key physicians regarding the proposed percent reduction. Implementation of a dose-rounding policy for these three agents represents a potentially substantial cost savings. [J Oncol Pharm Pract 2015;21:280-284]

A 2011 study by Winger and colleagues found that routine dose rounding of biologic anticancer agents to an amount within 10 percent of the ordered dose resulted in cost savings through reduction of drug wastage. [J Oncol Pharm Pract 2011;17:246-251]

The current study was a single-arm, retrospective chart review evaluating all monoclonal antibody doses dispensed at an outpatient community infusion centre associated with an academic medical centre between August 2014 and August 2015.The authors reviewed all monoclonal antibody doses to determine the cost of drug wasted using two methods.

The waste-cost analysis described the amount of drug disposed of due to the use of partial vials, while the theoretical dose savings described potential cost savings based on rounding the ordered dose to the nearest vial size. To explore clinical implications, a comparison was made between the theoretical rounded dose and the actual ordered dose.

“Monoclonal antibodies possess unique pharmacokinetic properties that permit flexible dosing,” the authors said. “Increased use and high costs of these medications have led to the development of cost-containing strategies.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 18 Feb 2016
Treatment with eluxadoline, a new oral medication, relieved two major symptoms of irritable bowel syndrome with diarrhoea (IBS-D) — abdominal pain and diarrhoea, according to a study based on two phase III randomized controlled trials. [N Engl J Med 2016;374:242-253]
Roshini Claire Anthony, 20 Mar 2018

Individuals with type 2 diabetes (T2D) who initiate therapy with sodium glucose cotransporter-2 (SGLT-2) inhibitors have lower risks of all-cause death and cardiovascular (CV) outcomes, specifically myocardial infarction (MI) and stroke, compared with those who initiate other glucose-lowering therapies, according to results from the CVD-REAL* 2 study.

Jairia Dela Cruz, 05 Mar 2018
Abaloparatide appears to produce significant increases in the bone mass density (BMD), as well as nominal reductions in fractures, in very elderly women with osteoporosis, with a safety profile similar to that in the overall study population, according to a posthoc analysis of the phase III ACTIVE trial.
Jairia Dela Cruz, 09 Jan 2017
The sulfonylurea glimepiride may pose an increased risk of hypoglycaemia in a subgroup of elderly type 2 diabetes (T2D) patients with lower β-cell function when added to a metformin regimen, according to a post-hoc analysis of data from the GENERATION* trial.